TABLE 3.
Antiphospholipid antibodies and their association with thrombosis
| Antiphospholipid antibody, n | Thrombosis (N = 58) | No thrombosis (N = 111) | Unadjusted OR (95% CI) | Adjusted OR (95% CI) b |
|---|---|---|---|---|
| LA positive, any test | 17 | 23 | 1.6 (0.8–3.3) | 1.6 (0.8–3.4) |
| dRVVT | 15 | 14 | 2.4 (1.1–5.4) | 2.5 (1.1–5.7) |
| LA‐sensitive aPTT a | 8 | 11 | 1.3 (0.5–3.3) | 1.2 (0.4–3.4) |
| Both tests positive | 6 | 2 | NA | NA |
| aCL IgM | 2 | 13 | 0.3 (0.1–1.2) | 0.2 (0.1–1.1) |
| aCL IgG | 3 | 11 | 0.5 (0.1–1.9) | 0.4 (0.1–1.4) |
| aβ2GPI IgM | 19 | 30 | 1.3 (0.7–2.6) | 1.5 (0.7–3.1) |
| aβ2GPI IgG | 22 | 42 | 1.0 (0.5–1.9) | 1.0 (0.5–1.9) |
| aPS/PT IgM | 11 | 24 | 0.8 (0.4–1.9) | 1.0 (0.4–2.2) |
| aPS/PT IgG | 0 | 1 | NA | NA |
Abbreviations: aCL, anticardiolipin antibody; aPS/PT, antiphosphatidylserine/prothrombin antibody; aPTT, activated partial thromboplastin time; aβ2GPI, anti‐β2‐glycoprotein I antibody; dRVVT, dilute Russell's viper venom time; LA, lupus anticoagulant; NA, not analyzed; OR, odds ratio.
a
Data were missing in 22 patients (3 patients with thrombosis, 19 patients without thrombosis) due to activated FX levels that exceeded the threshold for reliable LA‐sensitive aPTT test outcome.
b
Adjusted for the confounding variables sex, length of stay at the ICU, history of arterial or venous thrombosis, hypertension, and hypercholesterolemia.